Learn About Abacavir and Its Role in HIV Care

Abacavir is an antiretroviral medicine used as part of combination treatment for HIV. It belongs to the nucleoside reverse transcriptase inhibitor class and works by interfering with HIV replication. Before abacavir is started, HLA B5701 testing is recommended because people with this genetic variation have a significantly higher risk.

How Abacavir Supports HIV Treatment

Abacavir is converted inside cells into an active form that interferes with HIV reverse transcriptase. This enzyme is needed by HIV to convert its genetic material into DNA. By interfering with this process, abacavir helps reduce HIV replication.

The medicine may be included in combination regimens containing other antiretroviral medicines. The specific treatment selected depends on factors such as a person's medical history, other medications, HIV resistance information, and other health considerations.

Key points about its role include:

  • Abacavir is an NRTI used as part of combination antiretroviral therapy.
  • It helps suppress HIV replication rather than eliminating HIV from the body.
  • It may be available as an individual medicine or in combination products.
  • Treatment should be taken according to the regimen prescribed by a healthcare professional.
  • HIV medicines should not be stopped or changed without medical guidance.

HLA B5701 Testing and Safety Considerations

One of the most important considerations before using abacavir is the risk of a serious hypersensitivity reaction. This reaction can affect multiple organs and may become life-threatening. The risk is substantially higher in people who carry the HLA B5701 genetic variation. Current NIH guidance recommends HLA B5701 testing before starting abacavir, and people who test positive should not receive the medicine.

Important safety considerations include:

  • HLA B5701 testing should be performed before starting abacavir when the person's status is not already documented.
  • Symptoms of hypersensitivity can include fever, rash, gastrointestinal symptoms, fatigue, muscle or joint pain, and respiratory symptoms.
  • Hypersensitivity reactions commonly occur during the first several weeks of treatment.
  • Abacavir should not be restarted after a suspected or confirmed hypersensitivity reaction because a subsequent reaction can be severe.
  • A negative HLA B5701 result does not completely eliminate the possibility of a hypersensitivity reaction, so clinical monitoring remains important.

Abacavir can also be associated with other serious adverse effects, including lactic acidosis and liver-related problems. Healthcare professionals consider a person's medical history and other medicines when determining whether an abacavir-containing regimen is appropriate.

Abacavir continues to have a role in HIV care for selected patients, although treatment guidelines have changed as additional antiretroviral options have become available. Current NIH guidance notes that some abacavir-containing regimens are used in specific clinical situations rather than being preferred initial therapy for most people.

Understanding abacavir therefore involves more than knowing how the medicine affects HIV. Genetic testing, recognition of hypersensitivity symptoms, medical history, other medications, and the overall combination of antiretroviral medicines are important parts of its safe use. The information provided here is educational and is not intended as medical or treatment advice.